Summary
SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.
History
Founded in 2019, SD BioSensor has grown to become a leader in providing medical imaging technologies. Our innovative systems combine visual imaging and computer-aided detection (CAD) algorithms to help medical professionals and researchers improve patient care and outcomes.
Mission
Our mission is to help create a healthier, safer world by merging the most advanced medical technologies with practical, insightful industry experience.
Vision
We envision a world where everyone has access to advanced medical technologies that enable earlier diagnosis, improved treatments, and better outcomes for patients.
Key Team
Hyo Keun Lee (Vice Chairman & CEO)
Chul-Gyu Oh (CFO & Director)
Tae Young Heo (Pres & CEO)
Recognition and Awards
SD BioSensor has won numerous awards including the Top 10 Innovative Robotics & Machines Award from the IEEE Robotics and Automation Society, the Innovate UK-Home Office Award, and the Fujifilm Research Award.
References